June 27, 2018 10:19 AM EDT
News Briefing

Chi­nese I/O play­er Ad­lai Nortye wraps $50M Se­ries B; Am­gen touts PhI­II da­ta for Rem­i­cade knock­off

John Carroll

Editor & Founder

→ Hangzhou-based Ad­lai Nortye has gar­nered $50 mil­lion from some top do­mes­tic back­ers for its vi­sion in build­ing a glob­al im­munother­a­py com­pa­ny in Chi­na. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Cas­es of se­vere RSV in two Mod­er­na vac­cine can­di­dates' tri­als raise ques­tions about fu­ture

Ex­clu­sive: Two Vi­da Ven­tures co-founders ex­it the VC firm

Ear­ly da­ta on BTK de­graders sug­gest promise of next-gen ap­proach

Roche ini­tial­ly did­n't want to buy Po­sei­da — and part­ner Astel­las did­n't sub­mit an of­fer, new fil­ings show

'It's the bi­ol­o­gy, stu­pid': Re­la­tion and GSK team up on fi­bro­sis, os­teoarthri­tis

sponsored

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

A service from the Financial Times